
To explore the patterns of use of oral glucose lowering drugs (OGLDs) in Asian patients with type 2 diabetes (T2D) focusing on sulphonylureas (SU) and to describe the patient profiles according to treatment regimen. Amongst 62,512 patients (mean±SD age: 57.3±11.8 years; 53.6% men), 54,783 (87.6%) were treated with OGLDs at enrolment. Most received one (37.5%) or two (44.2%) OGLDs. In the entire cohort, 59.4% of treated patients received SU‐based therapy with variations amongst countries/regions. In Asia, SU is a popular OGLD class, often combined with metformin. Good glycaemic control and safety profiles associated with the use of SU including gliclazide support their position as a key treatment option in patients with T2D.
Like
Save
Share